Connect with us

Politics

More Than 500 People Have Commented On USDA Hemp Rules So Far

Published

on

Less than two weeks after the U.S. Department of Agriculture (USDA) opened a public comment period on proposed hemp regulations, more than 500 people have already weighed in.

USDA issued an interim final rule last month, laying out basic regulatory guidelines for hemp manufacturers. It contains information on a wide-range of issues, including licensing, THC testing requirements and the disposal process for crops the exceed potency limits.

Advocates and industry stakeholders have expressed mixed feelings about the rules. While the release of the regulations represents a positive development, with farmers soon to be equipped with the tools needed to fully enter the market, there are certain provisions that businesses have regarded as excessively restrictive and possibly damaging to the industry.

Those concerns, and others, are reflected in the comments submitted so far. Here are some highlights:

Christopher Gromek, a Washington State-based hemp business owner, said that USDA should allow growers to address so-called “hot” hemp containing excess THC before the crops are ripped up and thrown out.

“The USDA should allow farmers to remediate THC levels in ‘hot’ hemp by allowing them to (through sunlight/time etc. degrade the THC levels in their hemp until they are suitable for sale,” he said. “If farmers are allowed to remediate ‘hot’ hemp prior to sale, they’ll still be able to utilize most currently available genetic stock, while simply adding a processing requirement to ensure hemp of required THC levels is being sold.”

A significant number of people voiced frustration over the THC limit and how it will be tested for, with multiple stakeholders saying that testing should be limited to delta-9 THC, not the entire spectrum of THC content.

“As a farmer and someone who has worked in the processing of hemp,” Barbara Sisson said. “I am concerned with the matter of the total THC being used against farmers within the industry. This is something that needs much further research.”

“Testing of hemp to determine compliance with the 0.3% THC limit should not be done post-decarboxylation,” Zachary Farber wrote. “Doing so will make it significantly harder for hard-working hemp farmers to produce legal hemp.”

“The current testing requirements are already sufficient to ensure no psychoactive effects will be elicited from smoking the plant material,” he said. “The current available genetics would make it incredibly difficult for farmers to comply with the regulations.”

Several commenters recommended that the allowable THC content be increased from 0.3 percent to 1 percent, and some advised that the timeline for testing should be amended.

“We absolutely need a 30 day or more prior to harvest testing window, 15 days is not enough time to harvest,” one person said.

Another person weighed in on the proposed ban on being a “key principal” of a hemp business for those with felony drug convictions. While the ban expires after 10 years—a compromise that advocates hashed out with lawmakers—an anonymous commenter said “it is inconceivable that those most negatively impacted from prohibition would be barred from participating in the new legal economy.”

An Oregon-based hemp farmer raised an interesting point with respect to the requirement stipulating that only Drug Enforcement Administration (DEA)-registered facilities can test the crop. Jesse Richardson said the only such facility in the state is the Oregon State Crime Lab.

“From our understanding, many existing labs are unable to be DEA certified because they also service marijuana businesses, which is still a Schedule 1 Substance under the CSA,” Richardson said. “A single lab cannot handle 750+ growers in Oregon. Existing labs should be permitted service providers. These are quality, trusted labs we have worked with for years.”

In a related development, the advocacy organization U.S. Hemp Roundtable sent a letter on Tuesday thanking USDA for developing the interim rule and allowing stakeholders to submit input on the proposals. It pointed to a number of elements that the group “applaud[s]” such as one stipulating that interstate transportation of hemp products is permissible and another that provides some flexibility in THC testing.

But group’s message to USDA Under Secretary Greg Ibach also makes clear it is concerned about provisions that penalize farmers for cultivating hemp with more than 0.5 percent THC, require farmers to destroy unauthorized crops that could instead be used as a “soil amendment” or for research purposes, force hemp to be tested only in laboratories registered with the DEA and mandate that testing be done within 15 days from harvest.

“Resolution of these issue could have a positive impact on the developing hemp market, as well as promote future innovation,” the group wrote, adding that it  plans to formally submit a comment to USDA soon.

People can submit comments through December 31, after which point USDA will work to finalize the interim final rule for hemp. It’s not clear to what extent it will take submitted recommendations into consideration and amend the regulations; however, as U.S. Hemp Roundtable pointed out, the department appears to be receptive to feedback.

Meanwhile, the industry is still awaiting draft rules for hemp-derived CBD products from the Food and Drug Administration (FDA). Officials from the agency have indicated that there are complicating factors that make it difficult to develop regulations for the cannabis compound, and former FDA Commissioner Scott Gottlieb said it may take years for rules to be released without congressional action.

New York State Regulators File Amendment To Allow CBD Hemp Products In Medical Marijuana Program

Photo courtesy of Pixabay.

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.

Kyle Jaeger is Marijuana Moment's Los Angeles-based associate editor. His work has also appeared in High Times, VICE and attn.

Business

Marijuana Industry Groups Ask States For Coronavirus Relief Loans That Feds Won’t Provide

Published

on

A coalition of marijuana industry associations sent a letter to governors and state treasurers on Wednesday, asking them to help secure financial relief that cannabis businesses are being denied by the federal government amid the coronavirus outbreak.

The letter emphasizes that marijuana companies are providing jobs and essential services during the pandemic, and some are producing needed medical supplies like hand sanitizer. Despite this, the cannabis industry is specifically ineligible for federal disaster loans and other relief programs due to their product’s ongoing status as an illegal controlled substance. The groups said the treasurers could provide assistance to that end.

“Like all essential businesses, cannabis businesses are facing significant uncertainty and costs to provide for our employees and to maintain the medical supply chain during this pandemic,” the groups said. “Yet, unlike every other essential business, there is an underlying federal-state tension which puts our businesses in a uniquely vulnerable and dire operational and financial position. This is particularly true of our small and minority-owned businesses.”

They made two requests to the state officials: 1) encourage congressional delegations to insert language into future COVID-19 legislation that would enable marijuana companies to access federal Small Business Administration (SBA) relief loans and disaster assistance, and 2) consider creating state-level lending programs for the industry to help fill the gap in the meantime.

“Although cannabis businesses operate in strict compliance with state law and comply with a broad range of federal mandates, including paying federal corporate taxes at a much higher effective rate than other businesses due to a quirk in the tax code, their activity is still considered illegal under federal law,” the letter states. “This creates all kinds of hardship, including this current prohibition on SBA assistance.”

“While the underlying federal issues with banking, taxes, and capital access remain, our businesses need access to some additional liquidity to ensure reliability in the medical supply chain for patient access and employee retention in these uncertain times,” they said.

The National Cannabis Industry Association (NCIA), Marijuana Policy Project, Minority Cannabis Industry Association, Cannabis Trade Federation, National Cannabis Roundtable and Global Alliance for Cannabis Commerce each signed the letter.

“The cannabis industry is under the same strains as many other industries in these difficult times, in addition to existing unduly burdensome regulatory and financial requirements,” Morgan Fox, NCIA media relations director, said on behalf of the groups in a statement to Marijuana Moment. “Given the increasing recognition of cannabis businesses as necessary components of healthcare and economic stability, it is absolutely vital that they can access relief loans to continue to provide services effectively.”

SBA has made clear that its services are not available to marijuana businesses, or even those that indirectly work with the industry. While eleven senators recently requested that a key committee approve spending bill language allowing SBA program access to cannabis companies, the request was targeted at future spending legislation in the works, rather than bills concerning the coronavirus outbreak that will likely be enacted in short order.

In a separate letter to governors and regulators in states with medical cannabis programs, another set of industry and advocacy organizations stressed the need to maintain access to medical cannabis for patients. They thanked the states for deeming dispensaries to be essential services and said, additionally, they should allow home deliveries, curbside pickup, recommendations via telemedicine and remove or reduce caregiver application fees, among other steps.

“On behalf of medical cannabis businesses, patients, and our communities, we again express our gratitude for your leadership and work to ensure continued access to safe and effective medicine,” the groups, which includes all of those in the aforementioned letter as well as Americans for Safe Access and NORML. “We welcome the opportunity to help identify and implement safe means to ensure continued access to medicine.”

Read the letter concerning financial relief below:

Cannabis industry letter to… by Marijuana Moment on Scribd

Read the letter concerning medical cannabis access below: 

Industry group on medical c… by Marijuana Moment on Scribd

Lawmakers Mourn Loss Of Charlotte Figi, Whose Story Inspired National CBD Movement And Helped Change Policies

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.
Continue Reading

Culture

Lawmakers Mourn Loss Of Charlotte Figi, Whose Story Inspired National CBD Movement And Helped Change Policies

Published

on

Advocates and lawmakers are mourning the loss of a young icon in the medical marijuana reform movement. Charlotte Figi, who showed the world how CBD can treat severe epilepsy, passed away on Tuesday at the age of 13 due to complications from a likely coronavirus infection.

Across social media, people are sending their support to the Figi family and sharing anecdotes about how Charlotte’s battle against Dravet syndrome—and the success she demonstrated in treating it with the cannabis compound—changed hearts and minds. Her impact has been felt across state legislatures and in Congress, where her story was often told as a clear example of why laws prohibiting access to cannabidiol needed to change.

The domino effect Charlotte’s story helped set off—with states, particularly conservative ones, passing modest reform bills for CBD access—paved the path for a successful congressional rider that ended up protecting more far-reaching medical cannabis programs across the U.S., advocates say.

Rep. Matt Gaetz (R-FL), who has become one of the leading GOP champions for broad marijuana reform on Capitol Hill, said he was personally influenced by Charlotte and, as a state lawmaker in 2014, her story motivated him to support legislation to reform Florida’s medical cannabis policies.

“Charlotte lived a life of tremendous significance. Her story inspired me to completely change my views on medical cannabis and successfully pass legislation so that patients could get help in Florida,” the congressman said. “I’m so sad she is gone, but the movement she has ignited will live forever.”

Sen. Cory Gardner (R-CO), another top marijuana reform advocate who has raised the issue directly with President Trump on several occasions, wrote that Charlotte “made a positive and everlasting change in the world by the age of 13, and her inspirational courage will always be remembered.”

“Charlotte changed the way the nation thinks about CBD through her grace and advocacy,” he said. “We should honor her by fixing our federal cannabis laws as soon as possible.”

Florida state Rep. Rob Bradley (R) agreed with the sentiment, writing that “Charlotte Figi was a bright, beautiful light that changed how our state and country views cannabis. I am saddened to hear that this sweet soul has left us.”

In Illinois, state Rep. Bob Morgan (D) said Charlotte, who is the namesake of one of the most well-known CBD brands, Charlotte’s Web, “singlehandedly transformed how the world viewed medical cannabis and children with epilepsy.”

“She suffered so much so that others would not have to,” he said. “May her memory be a blessing.”

Pennsylvania state Sen. Daylin Leach (D) also said Charlotte “inspired me to get involved in the cannabis movement” and “showed the world that Cannabis is medicine and the trail she blazed has helped millions.”

“The world lost a fighter,” Missouri Attorney General Eric Schmitt, who previously advocated for CBD reform as a state senator, said. “Charlotte Figi-who helped inspire passage of CBD Oil legislation for epilepsy treatment nationwide-passed away. I worked w/her mom/others in 14 in MO. My speech in the Senate was a tribute to her, June Jesse, my son & many others.”

Beyond championing a successful CBD bill in Florida, Charlotte’s family also captivated national audiences and became a household name in the reform movement. Her story was featured on a popular CNN documentary, “Weed,” hosted by Sanjay Gupta, that introduced people from diverging political ideologies to an issue that’s since become a focus of legislation across the country.

A bipartisan congressional bill named after her—the Charlotte’s Web Medical Access Act—was first introduced in 2015.

But while that standalone legislation didn’t advance, the growing number of state-level policy changes that were inspired by Charlotte and other young patients could help to explain why Congress, including members who oppose legalization, has consistently supported a budget rider that prohibits the Justice Department from interfering in state-legal medical cannabis programs. It was first approved in 2014—after repeatedly failing on the House floor—and has been renewed each year since.

With CBD-only states included on an enumerated list of those that would be protected from legal action, it became increasingly difficult for lawmakers to defend voting against a measure to prevent federal harassment of their own constituents. Support from more conservative-minded Democrats and a handful of Republicans, including those from states that had recently enacted or were debating their own CBD laws, allowed the amendment to narrowly advance for the first time when it had been handily defeated two years earlier.

Alabama, Florida, Iowa, Kentucky and South Carolina stand out as examples of states where cannabis reform came online between those votes and where support for the measure also increased among their congressional delegations.

The measure as approved by Congress and first signed into law law President Obama, has given explicit protection from federal prosecution not just to people complying with limited CBD-focused state laws but also medical cannabis growers, processors and retailers in states with more robust policies such as California and Colorado (though it does not protect recreational marijuana businesses or consumers).

“Charlotte Figi personalized this issue in a way that few others have, and her story humanized the medical cannabis fight to such a degree that many politicians could no longer ignore it,” Paul Armentano, deputy director of NORML, told Marijuana Moment. “There is little doubt that Charlotte’s story, arguably more than any other, paved the way for politicians in several southern and midwestern states to finally move forward to recognize the need for CBD, and in some cases, whole-plant cannabis access.”

Don Murphy, director of federal policies for the Marijuana Policy Project, said even opponents of cannabis legalization “can’t say ‘no’ to young mothers pushing sick kids in strollers,” referencing the many other patient advocates who helped usher the reform to victory.

“There’s no doubt it helped move the debate in our direction,” he said. “Truth is, I was once told that CBD hurt our effort [for broader reform]. I don’t think so.”

A person writing on behalf of the family on Tuesday said that “Charlotte is no longer suffering” and will be forever seizure-free.

CBD Prescription Drug Is No Longer A Federally Controlled Substance, DEA Says

Image element courtesy of Paige Figi.

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.
Continue Reading

Politics

FBI Policy On CBD Use By Agents Is ‘Under Review’

Published

on

The Federal Bureau of Investigation (FBI) is apparently looking into changing internal policy when it comes to the use of CBD products by its agents and other employees, the agency said on Tuesday.

While workers are prohibited from using marijuana—and applicants can be disqualified for consuming cannabis within the past three years—it seems FBI is open to loosening rules for the non-intoxicating cannabis compound, which has become more widely available since hemp was federally legalized under the 2018 Farm Bill, creating a massive market for its derivatives.

During a Q&A on Twitter, FBI’s Newark office was asked two marijuana-related questions. One person wanted to know why the agency says “you cannot use marijuana within 3 years of applying, even with a medical card/prescription.”

“The policy regarding CBD oil is currently under review,” FBI replied. “Check the other eligibility requirements.”

The overall thread was about questions people had about the process of becoming a special agent, so it’s not clear if the CBD policy is being reevaluated for applicants only regarding past use, or if any change would cover active agents as well. Marijuana Moment reached out to FBI and its Newark division for clarification, but representatives did not respond by the time of publication.

Another person asked whether the three-year cannabis abstinence requirement applies to positions other than special agents and FBI said: “Yes, that policy applies to all positions within the FBI.”

The simple fact that FBI fielded multiple marijuana questions while promoting recruitment seems to speak to a point that the agency’s former director, James Comey, made in 2014. He suggested that he wanted to loosen the agency’s employment policies as it concerns marijuana, as potential skilled workers were being passed over due to the requirement.

“I have to hire a great work force to compete with those cyber criminals and some of those kids want to smoke weed on the way to the interview,” he said at the time.

Last year, FBI said it wanted the public to send tips on illicit activity in state-legal marijuana markets, stating that restrictive licensing policies could open the door to corruption.

While FBI’s CBD policy is in review, other federal agencies—particularly for within the military—have strongly discouraged or outright banned its use.

The Department of Defense made clear that CBD is off limits for service members.

The Air Force issued a notice last year stipulating that its members are prohibited from using the compound.

The Navy told its ranks that they’re barred from using CBD regardless of its legal status.

And the Coast Guard said last year that sailors can’t use marijuana or visit state-legal dispensaries.

Meanwhile, NASA said that CBD products could contain unauthorized THC concentrations that could jeopardize jobs if employees fail a drug test.

The Substance Abuse and Mental Health Services Administration issued guidance to federal agency drug program coordinators last year, expressing concern about excess THC in CBD products, which seems to have prompted the various departments to clarify their rules.

The Department of Transportation took a different approach in February, stating in a notice that it would not be testing drivers for CBD.

While much of the CBD found in markets across the U.S. is largely unregulated, as the Food and Drug Administration is in the process of developing rules for the compound, a CBD-based prescription medication for epilepsy was entirely removed from the Controlled Substances Act this week, which should lead to easier access for patients.

People Could Still Be Denied These Jobs Over Marijuana Use Under New York City Drug Testing Exemptions

Photo by Kimzy Nanney.

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.
Continue Reading
Advertisement

Marijuana News In Your Inbox

Support Marijuana Moment

Marijuana News In Your Inbox

Do NOT follow this link or you will be banned from the site!